|
|
|
Registry of biomedical companies:
[3] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 460 active entries
2910 Seventh Street
Berkeley, CA, USA 94710
Toll free: 800-246-9662
Phone: 510-644-1170
Fax: 510-644-0539
E-Mail:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Description:
XOMA Corporation is a biopharmaceutical company incorporated in 1981
XOMA Corporation (Nasdaq: XOMA) develops biopharmaceutical products to treat serious bacterial and fungal infections, infectious complications, and immune system diseases including organ transplant rejection.
The company's core technology is in the development and manufacturing of recombinant proteins and peptides, primarily those derived from the host-defense protein BPI (bactericidal/permeability-increasing protein). XOMA's technologies also include monoclonal antibodies, immunofusion molecules, and mammalian and bacterial cell expression systems.
XOMA has a pipeline of therapeutic drugs in development, including Neuprex(TM) (rBPI-21), the first product derived from the BPI molecule. Neuprex(TM) is in Phase II and III clinical trials for multiple indications. Additional BPI-derived products are in preclinical development, including I-PREX(TM), an ophthalmic formulation of rBPI-21, and Mycoprex(TM), an antifungal peptide.
Through a collaborative agreement with Genentech, XOMA is developing hu1124, an anti-CD11a monoclonal antibody for psoriasis and organ transplant rejection, now in Phase I studies in psoriasis.
XOMA's corporate strategy is to develop products from research through scaleup, clinical trials and regulatory approval, and to seek partners for commercialization, marketing and sale of approved products.
Last update of this entry: before October 1999.
|